Literature DB >> 17195033

Inhaling medicines: delivering drugs to the body through the lungs.

John S Patton1, Peter R Byron.   

Abstract

Remarkably, with the exception of anaesthetic gases, the ancient human practice of inhaling substances into the lungs for systemic effect has only just begun to be adopted by modern medicine. Treatment of asthma by inhaled drugs began in earnest in the 1950s, and now such 'topical' or targeted treatment with inhaled drugs is considered for treating many other lung diseases. More recently, major advances have led to increasing interest in systemic delivery of drugs by inhalation. Small molecules can be delivered with very rapid action, low metabolism and high bioavailability; and macromolecules can be delivered without injections, as highlighted by the recent approval of the first inhaled insulin product. Here, we review these advances, and discuss aspects of lung physiology and formulation composition that influence the systemic delivery of inhaled therapeutics.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17195033     DOI: 10.1038/nrd2153

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  235 in total

1.  Controlled release pulmonary administration of curcumin using swellable biocompatible microparticles.

Authors:  Ibrahim M El-Sherbiny; Hugh D C Smyth
Journal:  Mol Pharm       Date:  2011-12-28       Impact factor: 4.939

2.  Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.

Authors:  P Worth Longest; Geng Tian; Ross L Walenga; Michael Hindle
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

3.  Formation of protein nano-matrix particles with controlled surface architecture for respiratory drug delivery.

Authors:  Philip Chi Lip Kwok; Amolnat Tunsirikongkon; William Glover; Hak-Kim Chan
Journal:  Pharm Res       Date:  2010-12-07       Impact factor: 4.200

Review 4.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

5.  Interaction and localization of synthetic nanoparticles in healthy and cystic fibrosis airway epithelial cells: effect of ozone exposure.

Authors:  Shama Ahmad; David O Raemy; Joan E Loader; Jenai M Kailey; Keith B Neeves; Carl W White; Aftab Ahmad; Peter Gehr; Barbara M Rothen-Rutishauser
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2011-10-18       Impact factor: 2.849

Review 6.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

7.  Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles.

Authors:  Chenchen Wang; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2010-03-26       Impact factor: 3.246

8.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

9.  Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.

Authors:  Oleg V Evgenov; Daniel S Kohane; Kenneth D Bloch; Johannes-Peter Stasch; Gian P Volpato; Evangelia Bellas; Natalia V Evgenov; Emmanuel S Buys; Mark J Gnoth; Amanda R Graveline; Rong Liu; Dean R Hess; Robert Langer; Warren M Zapol
Journal:  Am J Respir Crit Care Med       Date:  2007-09-13       Impact factor: 21.405

10.  Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355.

Authors:  Paul Matthias Diderichsen; Eugène Cox; Steven W Martin; Adriaan Cleton; Jakob Ribbing
Journal:  Clin Pharmacokinet       Date:  2013-06       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.